Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

Summary The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, wo...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Osteoporosis international Ročník 23; číslo 1; s. 317 - 326
Hlavní autori:	Freemantle, N., Satram-Hoang, S., Tang, E.-T., Kaur, P., Macarios, D., Siddhanti, S., Borenstein, J., Kendler, D. L.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Springer-Verlag 01.01.2012 Springer Nature B.V
Predmet:	Administration, Oral Aged Alendronate - administration & dosage Alendronate - adverse effects Alendronate - therapeutic use Alendronic acid Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bisphosphonates Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Bone mineral density Clinical trials Comparative studies Cross-Over Studies Denosumab Drug Administration Schedule Drug therapy Endocrinology Female Humans Injections, Subcutaneous Medication Adherence Medicine Medicine & Public Health Middle Aged Original Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology Patient Preference Post-menopause RANK Ligand - antagonists & inhibitors Rheumatology Tablets Treatment Outcome Womens health Adherence Persistence Alendronate Compliance Denosumab
ISSN:	0937-941X, 1433-2965, 1433-2965
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Summary The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, women reported greater satisfaction with injectable denosumab and preferred it over oral alendronate. Introduction Osteoporosis patients who are non-compliant or non-persistent with therapy may have suboptimal clinical outcomes. This 2-year, randomized, open-label, crossover study compared treatment adherence between subcutaneous denosumab, 60 mg every 6 months, and oral alendronate, 70 mg once weekly. Methods Postmenopausal women at 25 centers in the USA and Canada with bone mineral density T-scores −4.0 to −2.0 and no prior bisphosphonate use received alendronate then denosumab, or denosumab then alendronate, over successive 12-month periods. Adherence required both compliance (denosumab injections 6 months apart or ≥80% of alendronate tablets) and persistence (both denosumab injections or ≥2 alendronate doses in the last month and completion of the treatment period). Results Of the 250 women enrolled (124 alendronate, 126 denosumab), 221 entered the second year (106 denosumab, 115 alendronate). Denosumab was associated with less non-adherence than alendronate (first year, 11.9% vs 23.4%; second year, 7.5% vs 36.5%). Risk ratios for non-adherence, non-compliance, and non-persistence favored denosumab in both years ( p < 0.05). Of 198 subjects expressing treatment preference, 183 (92.4%) preferred the injections over the oral therapy. BMD improved further when subjects received denosumab after alendronate and remained stable when they received alendronate after denosumab. Conclusion Based on the final results of this crossover study after women had received each treatment for up to 1 year, postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets and reported increased treatment preference and satisfaction with injectable denosumab over oral alendronate.
AbstractList	The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, women reported greater satisfaction with injectable denosumab and preferred it over oral alendronate. Osteoporosis patients who are non-compliant or non-persistent with therapy may have suboptimal clinical outcomes. This 2-year, randomized, open-label, crossover study compared treatment adherence between subcutaneous denosumab, 60 mg every 6 months, and oral alendronate, 70 mg once weekly. Postmenopausal women at 25 centers in the USA and Canada with bone mineral density T-scores -4.0 to -2.0 and no prior bisphosphonate use received alendronate then denosumab, or denosumab then alendronate, over successive 12-month periods. Adherence required both compliance (denosumab injections 6 months apart or ≥80% of alendronate tablets) and persistence (both denosumab injections or ≥2 alendronate doses in the last month and completion of the treatment period). Of the 250 women enrolled (124 alendronate, 126 denosumab), 221 entered the second year (106 denosumab, 115 alendronate). Denosumab was associated with less non-adherence than alendronate (first year, 11.9% vs 23.4%; second year, 7.5% vs 36.5%). Risk ratios for non-adherence, non-compliance, and non-persistence favored denosumab in both years (p<0.05). Of 198 subjects expressing treatment preference, 183 (92.4%) preferred the injections over the oral therapy. BMD improved further when subjects received denosumab after alendronate and remained stable when they received alendronate after denosumab. Based on the final results of this crossover study after women had received each treatment for up to 1 year, postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets and reported increased treatment preference and satisfaction with injectable denosumab over oral alendronate.[PUBLICATION ABSTRACT] The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, women reported greater satisfaction with injectable denosumab and preferred it over oral alendronate. Osteoporosis patients who are non-compliant or non-persistent with therapy may have suboptimal clinical outcomes. This 2-year, randomized, open-label, crossover study compared treatment adherence between subcutaneous denosumab, 60 mg every 6 months, and oral alendronate, 70 mg once weekly. Postmenopausal women at 25 centers in the USA and Canada with bone mineral density T-scores -4.0 to -2.0 and no prior bisphosphonate use received alendronate then denosumab, or denosumab then alendronate, over successive 12-month periods. Adherence required both compliance (denosumab injections 6 months apart or ≥ 80% of alendronate tablets) and persistence (both denosumab injections or ≥ 2 alendronate doses in the last month and completion of the treatment period). Of the 250 women enrolled (124 alendronate, 126 denosumab), 221 entered the second year (106 denosumab, 115 alendronate). Denosumab was associated with less non-adherence than alendronate (first year, 11.9% vs 23.4%; second year, 7.5% vs 36.5%). Risk ratios for non-adherence, non-compliance, and non-persistence favored denosumab in both years (p < 0.05). Of 198 subjects expressing treatment preference, 183 (92.4%) preferred the injections over the oral therapy. BMD improved further when subjects received denosumab after alendronate and remained stable when they received alendronate after denosumab. Based on the final results of this crossover study after women had received each treatment for up to 1 year, postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets and reported increased treatment preference and satisfaction with injectable denosumab over oral alendronate. The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, women reported greater satisfaction with injectable denosumab and preferred it over oral alendronate.UNLABELLEDThe final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, women reported greater satisfaction with injectable denosumab and preferred it over oral alendronate.Osteoporosis patients who are non-compliant or non-persistent with therapy may have suboptimal clinical outcomes. This 2-year, randomized, open-label, crossover study compared treatment adherence between subcutaneous denosumab, 60 mg every 6 months, and oral alendronate, 70 mg once weekly.INTRODUCTIONOsteoporosis patients who are non-compliant or non-persistent with therapy may have suboptimal clinical outcomes. This 2-year, randomized, open-label, crossover study compared treatment adherence between subcutaneous denosumab, 60 mg every 6 months, and oral alendronate, 70 mg once weekly.Postmenopausal women at 25 centers in the USA and Canada with bone mineral density T-scores -4.0 to -2.0 and no prior bisphosphonate use received alendronate then denosumab, or denosumab then alendronate, over successive 12-month periods. Adherence required both compliance (denosumab injections 6 months apart or ≥ 80% of alendronate tablets) and persistence (both denosumab injections or ≥ 2 alendronate doses in the last month and completion of the treatment period).METHODSPostmenopausal women at 25 centers in the USA and Canada with bone mineral density T-scores -4.0 to -2.0 and no prior bisphosphonate use received alendronate then denosumab, or denosumab then alendronate, over successive 12-month periods. Adherence required both compliance (denosumab injections 6 months apart or ≥ 80% of alendronate tablets) and persistence (both denosumab injections or ≥ 2 alendronate doses in the last month and completion of the treatment period).Of the 250 women enrolled (124 alendronate, 126 denosumab), 221 entered the second year (106 denosumab, 115 alendronate). Denosumab was associated with less non-adherence than alendronate (first year, 11.9% vs 23.4%; second year, 7.5% vs 36.5%). Risk ratios for non-adherence, non-compliance, and non-persistence favored denosumab in both years (p < 0.05). Of 198 subjects expressing treatment preference, 183 (92.4%) preferred the injections over the oral therapy. BMD improved further when subjects received denosumab after alendronate and remained stable when they received alendronate after denosumab.RESULTSOf the 250 women enrolled (124 alendronate, 126 denosumab), 221 entered the second year (106 denosumab, 115 alendronate). Denosumab was associated with less non-adherence than alendronate (first year, 11.9% vs 23.4%; second year, 7.5% vs 36.5%). Risk ratios for non-adherence, non-compliance, and non-persistence favored denosumab in both years (p < 0.05). Of 198 subjects expressing treatment preference, 183 (92.4%) preferred the injections over the oral therapy. BMD improved further when subjects received denosumab after alendronate and remained stable when they received alendronate after denosumab.Based on the final results of this crossover study after women had received each treatment for up to 1 year, postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets and reported increased treatment preference and satisfaction with injectable denosumab over oral alendronate.CONCLUSIONBased on the final results of this crossover study after women had received each treatment for up to 1 year, postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets and reported increased treatment preference and satisfaction with injectable denosumab over oral alendronate. The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, women reported greater satisfaction with injectable denosumab and preferred it over oral alendronate. Introduction: Osteoporosis patients who are non-compliant or non-persistent with therapy may have suboptimal clinical outcomes. This 2-year, randomized, open-label, crossover study compared treatment adherence between subcutaneous denosumab, 60 mg every 6 months, and oral alendronate, 70 mg once weekly. Methods: Postmenopausal women at 25 centers in the USA and Canada with bone mineral density T-scores -4.0 to -2.0 and no prior bisphosphonate use received alendronate then denosumab, or denosumab then alendronate, over successive 12-month periods. Adherence required both compliance (denosumab injections 6 months apart or greater than or equal to 80% of alendronate tablets) and persistence (both denosumab injections or greater than or equal to 2 alendronate doses in the last month and completion of the treatment period). Results: Of the 250 women enrolled (124 alendronate, 126 denosumab), 221 entered the second year (106 denosumab, 115 alendronate). Denosumab was associated with less non-adherence than alendronate (first year, 11.9% vs 23.4%; second year, 7.5% vs 36.5%). Risk ratios for non-adherence, non-compliance, and non-persistence favored denosumab in both years (p<0.05). Of 198 subjects expressing treatment preference, 183 (92.4%) preferred the injections over the oral therapy. BMD improved further when subjects received denosumab after alendronate and remained stable when they received alendronate after denosumab. Conclusion: Based on the final results of this crossover study after women had received each treatment for up to 1 year, postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets and reported increased treatment preference and satisfaction with injectable denosumab over oral alendronate. Summary The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets. After receiving both treatments, women reported greater satisfaction with injectable denosumab and preferred it over oral alendronate. Introduction Osteoporosis patients who are non-compliant or non-persistent with therapy may have suboptimal clinical outcomes. This 2-year, randomized, open-label, crossover study compared treatment adherence between subcutaneous denosumab, 60 mg every 6 months, and oral alendronate, 70 mg once weekly. Methods Postmenopausal women at 25 centers in the USA and Canada with bone mineral density T-scores −4.0 to −2.0 and no prior bisphosphonate use received alendronate then denosumab, or denosumab then alendronate, over successive 12-month periods. Adherence required both compliance (denosumab injections 6 months apart or ≥80% of alendronate tablets) and persistence (both denosumab injections or ≥2 alendronate doses in the last month and completion of the treatment period). Results Of the 250 women enrolled (124 alendronate, 126 denosumab), 221 entered the second year (106 denosumab, 115 alendronate). Denosumab was associated with less non-adherence than alendronate (first year, 11.9% vs 23.4%; second year, 7.5% vs 36.5%). Risk ratios for non-adherence, non-compliance, and non-persistence favored denosumab in both years ( p < 0.05). Of 198 subjects expressing treatment preference, 183 (92.4%) preferred the injections over the oral therapy. BMD improved further when subjects received denosumab after alendronate and remained stable when they received alendronate after denosumab. Conclusion Based on the final results of this crossover study after women had received each treatment for up to 1 year, postmenopausal women with osteoporosis were more adherent, compliant, and persistent with subcutaneous denosumab injections every 6 months than with once-weekly alendronate tablets and reported increased treatment preference and satisfaction with injectable denosumab over oral alendronate.
Author	Kaur, P. Kendler, D. L. Freemantle, N. Macarios, D. Tang, E.-T. Siddhanti, S. Borenstein, J. Satram-Hoang, S.
Author_xml	– sequence: 1 givenname: N. surname: Freemantle fullname: Freemantle, N. email: nicholas.freemantle@ucl.ac.uk organization: University of Birmingham, Department of Primary Care and Population Health, Upper Third Floor, UCL Medical School (Royal Free Campus) – sequence: 2 givenname: S. surname: Satram-Hoang fullname: Satram-Hoang, S. organization: Amgen Inc – sequence: 3 givenname: E.-T. surname: Tang fullname: Tang, E.-T. organization: Amgen Inc – sequence: 4 givenname: P. surname: Kaur fullname: Kaur, P. organization: Amgen Inc., David Geffen School of Medicine – sequence: 5 givenname: D. surname: Macarios fullname: Macarios, D. organization: Amgen Inc – sequence: 6 givenname: S. surname: Siddhanti fullname: Siddhanti, S. organization: Amgen Inc – sequence: 7 givenname: J. surname: Borenstein fullname: Borenstein, J. organization: Cedars-Sinai Health System – sequence: 8 givenname: D. L. surname: Kendler fullname: Kendler, D. L. organization: University of British Columbia
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/21927922$$D View this record in MEDLINE/PubMed
BookMark	eNqNkl9rFDEUxYNU7Lb6AXyR4IsKHc2fmZ2JD8LSWhUKFqrgW7ibudNNmUmmSaalfh4_qFl365-C4lMmzO_cnMs5e2THeYeEPObsJWesfhUZ46opGOcFrxtW8HtkxkspC6Hm1Q6ZMSXrQpX8yy7Zi_GCZY1S9QOyK7gStRJiRr4dWwc9DRinPkXqO5pWSI8Wp2f0-RE6H6cBlnTRrjCgM0hPA3bbzzNINnZgkvXuBY1pam9eU6CiLAbv0uqABnCtH-xXbA-oCT5Gf4WBGj-MEGz0jl7btKLQo2uDd5CQWkdHH9OQHx5hitnYtc-Xh-R-B33ER9tzn3w-fvvp8H1x8vHdh8PFSWEqxlIBXYklmtYIBF4hqEayNq8sWsWAcyiFausOG1YZs0QjhDSAvKmMVBUseSf3yZvN3HFaDtgadClAr8dgBwg32oPVf_5xdqXP_ZWWolSC8zzg2XZA8JcTxqQHGw32PTj0U9RKzJtGyHr-HyQTolFSZPLpHfLCTyGHliEueV2V5Rp68rvzn5Zvg85AvQF-BJFD1MYmWEeXF7G95kyvK6U3ldK5UnpdKb3eid9R3g7_l0ZsNDGz7hzDL89_F30H_JHhVw
CitedBy_id	crossref_primary_10_1007_s12020_019_01919_8 crossref_primary_10_1371_journal_pone_0193846 crossref_primary_10_1001_jamanetworkopen_2019_2416 crossref_primary_10_1002_art_41981 crossref_primary_10_3390_jcm10010152 crossref_primary_10_1007_s00198_015_3164_4 crossref_primary_10_1016_j_jbspin_2025_105954 crossref_primary_10_4158_GL_2020_0524SUPPL crossref_primary_10_1007_s00198_012_2093_8 crossref_primary_10_1007_s11657_021_01036_y crossref_primary_10_1185_03007995_2015_1065241 crossref_primary_10_21101_cejph_a6809 crossref_primary_10_1016_j_jocd_2024_101559 crossref_primary_10_1016_j_jbo_2025_100680 crossref_primary_10_1056_NEJMcp2307353 crossref_primary_10_1007_s11914_017_0380_1 crossref_primary_10_1080_14712598_2025_2540471 crossref_primary_10_3109_09513590_2014_892067 crossref_primary_10_1177_2381468318818843 crossref_primary_10_1016_j_bone_2020_115287 crossref_primary_10_1007_s00198_017_3940_4 crossref_primary_10_1007_s00223_016_0132_8 crossref_primary_10_1210_clinem_dgad449 crossref_primary_10_3390_jcm8070932 crossref_primary_10_1016_j_rhum_2018_02_005 crossref_primary_10_1016_j_semarthrit_2019_02_007 crossref_primary_10_1007_s00198_024_07351_7 crossref_primary_10_1007_s00198_025_07449_6 crossref_primary_10_1002_jbmr_3914 crossref_primary_10_1177_1049909114539035 crossref_primary_10_1210_clinem_dgz321 crossref_primary_10_1007_s00198_012_2115_6 crossref_primary_10_1007_s00774_022_01357_z crossref_primary_10_1007_s11657_021_00956_z crossref_primary_10_1016_j_bone_2020_115838 crossref_primary_10_1210_jc_2019_00777 crossref_primary_10_1001_jamanetworkopen_2024_43879 crossref_primary_10_1007_s00774_018_0955_7 crossref_primary_10_1007_s00198_019_05228_8 crossref_primary_10_1007_s00223_018_0404_6 crossref_primary_10_1016_j_rhum_2018_09_005 crossref_primary_10_1007_s11420_015_9469_1 crossref_primary_10_1007_s00198_015_3458_6 crossref_primary_10_1136_dtb_2013_5_0177 crossref_primary_10_1007_s00198_016_3623_6 crossref_primary_10_1080_17446651_2021_1956902 crossref_primary_10_1186_s12913_024_12189_0 crossref_primary_10_3389_fpsyt_2019_00200 crossref_primary_10_1016_j_jocd_2017_10_041 crossref_primary_10_1186_s12875_020_01103_2 crossref_primary_10_1007_s11657_023_01210_4 crossref_primary_10_1080_13697137_2021_1951697 crossref_primary_10_1186_s43094_024_00719_w crossref_primary_10_1210_clinem_dgaa007 crossref_primary_10_1002_jbmr_3039 crossref_primary_10_1007_s12325_016_0360_3 crossref_primary_10_1007_s43465_023_01064_5 crossref_primary_10_1007_s00223_017_0288_x crossref_primary_10_1016_j_bone_2021_115902 crossref_primary_10_1080_14397595_2020_1789319 crossref_primary_10_1097_GME_0b013e31828f5e5d crossref_primary_10_1007_s12020_012_9696_x crossref_primary_10_1007_s40266_014_0191_3 crossref_primary_10_1007_s11657_020_00796_3 crossref_primary_10_1007_s00198_014_2871_6 crossref_primary_10_1002_phar_2838 crossref_primary_10_1007_s00198_017_4242_6 crossref_primary_10_1007_s00198_019_05066_8 crossref_primary_10_1007_s11657_023_01263_5 crossref_primary_10_1016_j_bonr_2021_101105 crossref_primary_10_1186_s12962_016_0060_5 crossref_primary_10_1186_s40780_023_00315_9 crossref_primary_10_1007_s11657_017_0316_5 crossref_primary_10_1586_erp_12_76 crossref_primary_10_1016_j_jbspin_2017_12_013 crossref_primary_10_1177_20420188211010052 crossref_primary_10_1007_s00198_019_04913_y crossref_primary_10_1097_AOG_0b013e318291718c crossref_primary_10_1210_clinem_dgaa756 crossref_primary_10_1007_s00198_022_06595_5 crossref_primary_10_1007_s40256_022_00534_9 crossref_primary_10_1007_s00198_015_3334_4 crossref_primary_10_1136_rmdopen_2015_000051 crossref_primary_10_1007_s00198_022_06648_9 crossref_primary_10_1007_s00198_024_07118_0 crossref_primary_10_1210_clinem_dgab321 crossref_primary_10_1007_s00198_017_4144_7 crossref_primary_10_1007_s00198_022_06667_6 crossref_primary_10_1177_2150132719884300 crossref_primary_10_2217_cer_2020_0216 crossref_primary_10_3390_math9182331 crossref_primary_10_1007_s00774_024_01521_7 crossref_primary_10_1007_s11845_023_03383_w crossref_primary_10_1007_s11657_022_01145_2 crossref_primary_10_1016_j_bone_2013_11_002 crossref_primary_10_1097_MD_0000000000001674 crossref_primary_10_1016_j_bone_2019_06_012 crossref_primary_10_1007_s00198_018_4508_7 crossref_primary_10_1080_14656566_2025_2451741 crossref_primary_10_1177_1759720X221124543 crossref_primary_10_1007_s00198_017_3919_1 crossref_primary_10_1007_s00774_020_01126_w crossref_primary_10_1007_s11657_018_0509_6 crossref_primary_10_1136_bmj_2024_081250 crossref_primary_10_1136_bmj_2021_068033 crossref_primary_10_1210_clinem_dgae224 crossref_primary_10_1002_jbmr_3853 crossref_primary_10_1007_s42000_025_00708_5 crossref_primary_10_3390_jcm12010014 crossref_primary_10_1007_s40520_025_02991_z crossref_primary_10_1210_clinem_dgz095 crossref_primary_10_1002_jbm4_10396 crossref_primary_10_1002_jbmr_3051 crossref_primary_10_1007_s11657_018_0491_z crossref_primary_10_1007_s40258_013_0047_8 crossref_primary_10_1016_j_ando_2015_10_009 crossref_primary_10_1016_j_amjmed_2019_04_044 crossref_primary_10_1302_0301_620X_98B2_36161 crossref_primary_10_1016_j_oooo_2018_09_008 crossref_primary_10_1007_s11914_017_0376_x crossref_primary_10_1007_s00223_019_00616_y crossref_primary_10_1080_24725625_2019_1702494 crossref_primary_10_1155_2016_7903128 crossref_primary_10_1007_s00198_016_3553_3 crossref_primary_10_1111_1756_185X_14101 crossref_primary_10_1136_bmj_l4378 crossref_primary_10_1007_s13300_019_00718_8 crossref_primary_10_1016_j_bonr_2020_100290 crossref_primary_10_1007_s11136_022_03290_0 crossref_primary_10_1530_EJE_18_0056 crossref_primary_10_1007_s00198_019_05154_9 crossref_primary_10_1007_s40271_020_00417_8 crossref_primary_10_1016_j_pop_2025_01_008 crossref_primary_10_1007_s00198_017_4334_3 crossref_primary_10_1016_j_jbspin_2018_02_009 crossref_primary_10_1186_s13018_018_0865_3 crossref_primary_10_1002_jbmr_4098 crossref_primary_10_1080_14740338_2024_2386365 crossref_primary_10_1097_GRF_0000000000000572 crossref_primary_10_1155_2016_8738959 crossref_primary_10_1016_j_bonr_2020_100267 crossref_primary_10_1007_s00774_025_01586_y crossref_primary_10_1185_03007995_2015_1053049 crossref_primary_10_1111_clr_12556 crossref_primary_10_1155_2015_627631 crossref_primary_10_1111_bcp_13834 crossref_primary_10_3390_ijms22042105 crossref_primary_10_1007_s00198_023_06679_w crossref_primary_10_1016_j_metabol_2015_07_011 crossref_primary_10_1517_14740338_2014_860133 crossref_primary_10_1007_s00223_013_9724_8 crossref_primary_10_1210_jc_2019_00747 crossref_primary_10_1080_14740338_2018_1430764 crossref_primary_10_1093_jbmr_zjaf008 crossref_primary_10_1002_jbmr_4049 crossref_primary_10_1016_j_bone_2017_08_003 crossref_primary_10_1002_jbmr_3359 crossref_primary_10_1007_s11657_017_0413_5 crossref_primary_10_1007_s40619_021_00855_y crossref_primary_10_1210_jc_2019_00221 crossref_primary_10_1177_1759720X18805759 crossref_primary_10_1210_clinem_dgae240 crossref_primary_10_1007_s00198_015_3253_4 crossref_primary_10_1007_s11657_019_0664_4 crossref_primary_10_1186_s12916_025_03958_7 crossref_primary_10_1185_03007995_2015_1027186 crossref_primary_10_1097_GME_0000000000001141 crossref_primary_10_1016_j_maturitas_2018_11_010 crossref_primary_10_1007_s11926_015_0533_0 crossref_primary_10_1007_s40619_023_01207_8 crossref_primary_10_33393_dti_2021_2342 crossref_primary_10_1007_s12020_025_04430_5 crossref_primary_10_1080_24725625_2020_1832756 crossref_primary_10_1007_s00198_020_05502_0 crossref_primary_10_1007_s11657_022_01156_z crossref_primary_10_1177_1060028018768808 crossref_primary_10_1007_s00774_025_01631_w crossref_primary_10_1080_14656566_2020_1717468 crossref_primary_10_1007_s00198_016_3607_6 crossref_primary_10_1097_QAD_0000000000003704 crossref_primary_10_1007_s11914_022_00756_5 crossref_primary_10_1080_14656566_2023_2296543 crossref_primary_10_1097_QAI_0000000000003509 crossref_primary_10_3389_fendo_2024_1431676 crossref_primary_10_1007_s12325_021_01936_y crossref_primary_10_1080_14397595_2020_1769895 crossref_primary_10_1159_000503066 crossref_primary_10_1007_s00198_019_04963_2 crossref_primary_10_1007_s00198_013_2364_z crossref_primary_10_1097_RHU_0000000000000979 crossref_primary_10_1517_17425255_2015_1000860
Cites_doi	10.1007/s00198-008-0644-9 10.4065/82.12.1493 10.1080/08870449908407311 10.1258/095646204322637245 10.1016/j.jad.2005.08.018 10.1016/j.coph.2005.06.005 10.1185/030079904125004475 10.1001/jama.296.24.2927 10.1359/jbmr.070809 10.1007/s00198-009-1023-x 10.1080/713690213 10.1359/JBMR.040305 10.1093/annonc/mdj044 10.1007/s00198-010-1424-x 10.1007/s00198-004-1652-z 10.1007/s00198-009-1134-4 10.4065/81.8.1013 10.1056/NEJMoa044459 10.1016/j.bone.2005.10.022 10.1359/jbmr.080510 10.1097/01.mlr.0000185733.30697.f6 10.1359/jbmr.0809010 10.1016/j.bone.2006.01.150 10.1007/s00223-009-9329-4 10.1002/pds.2048 10.1056/NEJMoa0809493 10.18553/jmcp.2009.15.9.728 10.1007/s00198-010-1378-z
ContentType	Journal Article
Contributor	Akright, Bruce Lillestol, Michael McClung, Michael Kaiser, Stephanie Erlich, Elyse Joseph, John Kendler, David Waltin-James, Jerieta Gerrish, Catherine Lang, Robert Leeds, Leroy Saadeh, Constantine Fehnel, Stephen Datz, Kurt Williams, John Raynauld, Jean-Pierre Linden, Dennis Soufer, Joseph Adachi, Jonathan Tamayo, Raul Dikranian, Ara Michelson, Jefferey Moffett, Alfred Shockey, Gerald
Contributor_xml	– sequence: 1 givenname: Bruce surname: Akright fullname: Akright, Bruce – sequence: 2 givenname: Kurt surname: Datz fullname: Datz, Kurt – sequence: 3 givenname: Ara surname: Dikranian fullname: Dikranian, Ara – sequence: 4 givenname: Elyse surname: Erlich fullname: Erlich, Elyse – sequence: 5 givenname: Stephen surname: Fehnel fullname: Fehnel, Stephen – sequence: 6 givenname: Catherine surname: Gerrish fullname: Gerrish, Catherine – sequence: 7 givenname: John surname: Joseph fullname: Joseph, John – sequence: 8 givenname: Robert surname: Lang fullname: Lang, Robert – sequence: 9 givenname: Leroy surname: Leeds fullname: Leeds, Leroy – sequence: 10 givenname: Michael surname: Lillestol fullname: Lillestol, Michael – sequence: 11 givenname: Dennis surname: Linden fullname: Linden, Dennis – sequence: 12 givenname: Michael surname: McClung fullname: McClung, Michael – sequence: 13 givenname: Jefferey surname: Michelson fullname: Michelson, Jefferey – sequence: 14 givenname: Alfred surname: Moffett fullname: Moffett, Alfred – sequence: 15 givenname: Constantine surname: Saadeh fullname: Saadeh, Constantine – sequence: 16 givenname: Gerald surname: Shockey fullname: Shockey, Gerald – sequence: 17 givenname: Joseph surname: Soufer fullname: Soufer, Joseph – sequence: 18 givenname: Raul surname: Tamayo fullname: Tamayo, Raul – sequence: 19 givenname: John surname: Williams fullname: Williams, John – sequence: 20 givenname: Jonathan surname: Adachi fullname: Adachi, Jonathan – sequence: 21 givenname: Stephanie surname: Kaiser fullname: Kaiser, Stephanie – sequence: 22 givenname: David surname: Kendler fullname: Kendler, David – sequence: 23 givenname: Jean-Pierre surname: Raynauld fullname: Raynauld, Jean-Pierre – sequence: 24 givenname: Jerieta surname: Waltin-James fullname: Waltin-James, Jerieta
Copyright	The Author(s) 2011 International Osteoporosis Foundation and National Osteoporosis Foundation 2012
Copyright_xml	– notice: The Author(s) 2011 – notice: International Osteoporosis Foundation and National Osteoporosis Foundation 2012
CorporateAuthor	on behalf of the DAPS Investigators DAPS Investigators
CorporateAuthor_xml	– name: on behalf of the DAPS Investigators – name: DAPS Investigators
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7RV 7TS 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1007/s00198-011-1780-1
DatabaseName	Springer Nature Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Physical Education Index Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China Physical Education Index ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic Calcium & Calcified Tissue Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1433-2965
EndPage	326
ExternalDocumentID	PMC3249211 2550843201 21927922 10_1007_s00198_011_1780_1
Genre	Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 199 1N0 1SB 203 28- 29O 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z7W Z82 Z83 Z87 Z8O Z8Q Z8V Z8W Z91 ZMTXR ZOVNA ZXP ~A9 ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION EIHBH PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7QP 7TS 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c500t-af4e4ecdc2ea15ea9830d0792d90a11a429d7fe805ccbec223cae185c395ab1f3
IEDL.DBID	7X7
ISICitedReferencesCount	225
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000298645700030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0937-941X 1433-2965
IngestDate	Tue Nov 04 01:58:39 EST 2025 Thu Sep 04 19:19:16 EDT 2025 Fri Sep 05 09:40:04 EDT 2025 Tue Nov 04 19:46:00 EST 2025 Mon Jul 21 06:03:48 EDT 2025 Sat Nov 29 02:26:55 EST 2025 Tue Nov 18 21:31:33 EST 2025 Fri Feb 21 02:34:07 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Adherence Persistence Alendronate Compliance Denosumab
Language	English
License	This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c500t-af4e4ecdc2ea15ea9830d0792d90a11a429d7fe805ccbec223cae185c395ab1f3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://link.springer.com/10.1007/s00198-011-1780-1
PMID	21927922
PQID	913175442
PQPubID	33762
PageCount	10
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_3249211 proquest_miscellaneous_926882376 proquest_miscellaneous_920228932 proquest_journals_913175442 pubmed_primary_21927922 crossref_citationtrail_10_1007_s00198_011_1780_1 crossref_primary_10_1007_s00198_011_1780_1 springer_journals_10_1007_s00198_011_1780_1
PublicationCentury	2000
PublicationDate	2012-01-01
PublicationDateYYYYMMDD	2012-01-01
PublicationDate_xml	– month: 01 year: 2012 text: 2012-01-01 day: 01
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationSubtitle	With other metabolic bone diseases
PublicationTitle	Osteoporosis international
PublicationTitleAbbrev	Osteoporos Int
PublicationTitleAlternate	Osteoporos Int
PublicationYear	2012
Publisher	Springer-Verlag Springer Nature B.V
Publisher_xml	– name: Springer-Verlag – name: Springer Nature B.V
References	Caro, Ishak, Huybrechts, Raggio, Naujoks (CR5) 2004; 15 Gold, Horne, Hill, Borenstein, Varon, Macarios (CR23) 2008; 23 Hiligsmann, Rabenda, Gathon, Ethgen, Reginster (CR4) 2010; 86 Brown, Prince, Deal (CR19) 2009; 24 Gallagher, Rietbrock, Olson, van Staa (CR27) 2008; 23 Kothawala, Badamgarav, Ryu, Miller, Halbert (CR2) 2007; 82 Fallowfield, Atkins, Catt, Cox, Coxon, Langridge, Morris, Price (CR12) 2006; 17 Cummings, San Martin, McClung (CR20) 2009; 361 Ström, Borgström, Kanis, Jönsson (CR28) 2009; 20 Jönsson, Ström, Eisman, Papaioannou, Siris, Tosteson, Kanis (CR29) 2011; 22 Reginster, Rabenda, Neuprez (CR14) 2006; 38 McClung, Lewiecki, Cohen (CR17) 2006; 354 Kendler, Bessette, Hill (CR11) 2010; 21 Granger, Fehnel, Hogue, Bennett, Edin (CR13) 2006; 90 Imaz, Zegarra, Gonzalez-Enriquez, Rubio, Alcazar, Amate (CR1) 2010; 21 Brown, Battista, Bruehlman, Sereika, Thase, Dunbar-Jacob (CR8) 2005; 43 Kostenuik (CR15) 2005; 5 Kendler, McClung, Freemantle (CR21) 2011; 22 Briesacher, Andrade, Harrold, Fouayzi, Yood (CR24) 2010; 19 Byer, Myers (CR9) 2000; 5 Yeaw, Benner, Walt, Sian, Smith (CR7) 2009; 15 Horne, Weinman, Hankins (CR22) 1999; 14 Rodan, Reszka, Golub, Rizzoli (CR25) 2004; 20 Siris, Harris, Rosen, Barr, Arvesen, Abbott, Silverman (CR3) 2006; 81 Lewiecki, Miller, McClung, Cohen, Bolognese, Liu, Wang, Siddhanti, Fitzpatrick (CR18) 2007; 22 Bekker, Holloway, Rasmussen, Murphy, Martin, Leese, Holmes, Dunstan, DePaoli (CR16) 2004; 19 Huybrechts, Ishak, Caro (CR6) 2006; 38 Black, Schwartz, Ensrud (CR26) 2006; 296 Horne, Buick, Fisher, Leake, Cooper, Weinman (CR10) 2004; 15 J Yeaw (1780_CR7) 2009; 15 EM Lewiecki (1780_CR18) 2007; 22 R Horne (1780_CR10) 2004; 15 AM Gallagher (1780_CR27) 2008; 23 B Jönsson (1780_CR29) 2011; 22 ES Siris (1780_CR3) 2006; 81 MR McClung (1780_CR17) 2006; 354 KF Huybrechts (1780_CR6) 2006; 38 C Brown (1780_CR8) 2005; 43 PJ Bekker (1780_CR16) 2004; 19 R Horne (1780_CR22) 1999; 14 G Rodan (1780_CR25) 2004; 20 M Hiligsmann (1780_CR4) 2010; 86 O Ström (1780_CR28) 2009; 20 JP Brown (1780_CR19) 2009; 24 DT Gold (1780_CR23) 2008; 23 PJ Kostenuik (1780_CR15) 2005; 5 BA Briesacher (1780_CR24) 2010; 19 AL Granger (1780_CR13) 2006; 90 L Fallowfield (1780_CR12) 2006; 17 DM Black (1780_CR26) 2006; 296 B Byer (1780_CR9) 2000; 5 P Kothawala (1780_CR2) 2007; 82 DL Kendler (1780_CR11) 2010; 21 JY Reginster (1780_CR14) 2006; 38 JJ Caro (1780_CR5) 2004; 15 SR Cummings (1780_CR20) 2009; 361 1780_CR21 I Imaz (1780_CR1) 2010; 21
References_xml	– volume: 22 start-page: 1725 year: 2011 end-page: 1735 ident: CR21 article-title: Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate publication-title: Osteoporos Int – volume: 20 start-page: 23 year: 2009 end-page: 34 ident: CR28 article-title: Incorporating adherence into health economic modelling of osteoporosis publication-title: Osteoporos Int doi: 10.1007/s00198-008-0644-9 – volume: 82 start-page: 1493 year: 2007 end-page: 1501 ident: CR2 article-title: Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis publication-title: Mayo Clin Proc doi: 10.4065/82.12.1493 – volume: 14 start-page: 1 year: 1999 end-page: 24 ident: CR22 article-title: The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication publication-title: Psychol Health doi: 10.1080/08870449908407311 – volume: 15 start-page: 38 year: 2004 end-page: 44 ident: CR10 article-title: Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART publication-title: Int J STD AIDS doi: 10.1258/095646204322637245 – volume: 90 start-page: 217 year: 2006 end-page: 221 ident: CR13 article-title: An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey publication-title: J Affect Disord doi: 10.1016/j.jad.2005.08.018 – volume: 5 start-page: 618 year: 2005 end-page: 625 ident: CR15 article-title: Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2005.06.005 – volume: 20 start-page: 1291 year: 2004 end-page: 1300 ident: CR25 article-title: Bone safety of long-term bisphosphonate treatment publication-title: Curr Med Res Opin doi: 10.1185/030079904125004475 – volume: 296 start-page: 2927 year: 2006 end-page: 2938 ident: CR26 article-title: Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial publication-title: JAMA doi: 10.1001/jama.296.24.2927 – volume: 22 start-page: 1832 year: 2007 end-page: 1841 ident: CR18 article-title: Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD publication-title: J Bone Miner Res doi: 10.1359/jbmr.070809 – volume: 21 start-page: 837 year: 2010 end-page: 846 ident: CR11 article-title: Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass publication-title: Osteoporos Int doi: 10.1007/s00198-009-1023-x – volume: 15 start-page: 728 year: 2009 end-page: 740 ident: CR7 article-title: Comparing adherence and persistence across 6 chronic medication classes publication-title: J Manag Care Pharm – volume: 5 start-page: 389 year: 2000 end-page: 393 ident: CR9 article-title: Psychological correlates of adherence to medication in asthma publication-title: Psychol Health Med doi: 10.1080/713690213 – volume: 19 start-page: 1059 year: 2004 end-page: 1066 ident: CR16 article-title: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women publication-title: J Bone Miner Res doi: 10.1359/JBMR.040305 – volume: 17 start-page: 205 year: 2006 end-page: 210 ident: CR12 article-title: Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdj044 – volume: 22 start-page: 967 year: 2011 end-page: 982 ident: CR29 article-title: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis publication-title: Osteoporos Int doi: 10.1007/s00198-010-1424-x – volume: 15 start-page: 1003 year: 2004 end-page: 1008 ident: CR5 article-title: The impact of compliance with osteoporosis therapy on fracture rates in actual practice publication-title: Osteoporos Int doi: 10.1007/s00198-004-1652-z – volume: 21 start-page: 1943 year: 2010 end-page: 1951 ident: CR1 article-title: Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis publication-title: Osteoporos Int doi: 10.1007/s00198-009-1134-4 – volume: 81 start-page: 1013 year: 2006 end-page: 1022 ident: CR3 article-title: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases publication-title: Mayo Clin Proc doi: 10.4065/81.8.1013 – volume: 354 start-page: 821 year: 2006 end-page: 831 ident: CR17 article-title: Denosumab in postmenopausal women with low bone mineral density publication-title: N Engl J Med doi: 10.1056/NEJMoa044459 – volume: 38 start-page: 922 year: 2006 end-page: 928 ident: CR6 article-title: Assessment of compliance with osteoporosis treatment and its consequences in a managed care population publication-title: Bone doi: 10.1016/j.bone.2005.10.022 – volume: 23 start-page: 1569 year: 2008 end-page: 1575 ident: CR27 article-title: Fracture outcomes related to persistence and compliance with oral bisphosphonates publication-title: J Bone Miner Res doi: 10.1359/jbmr.080510 – volume: 43 start-page: 1203 year: 2005 end-page: 1207 ident: CR8 article-title: Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence publication-title: Med Care doi: 10.1097/01.mlr.0000185733.30697.f6 – volume: 23 start-page: S210 year: 2008 end-page: S211 ident: CR23 article-title: Development, reliability, and validity of a new preference satisfaction questionnaire (PSQ) publication-title: J Bone Miner Res – volume: 24 start-page: 153 year: 2009 end-page: 161 ident: CR19 article-title: Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial publication-title: J Bone Miner Res doi: 10.1359/jbmr.0809010 – volume: 38 start-page: S2 year: 2006 end-page: S6 ident: CR14 article-title: Adherence, patient preference and dosing frequency: understanding the relationship publication-title: Bone doi: 10.1016/j.bone.2006.01.150 – volume: 86 start-page: 202 year: 2010 end-page: 210 ident: CR4 article-title: Potential clinical and economic impact of nonadherence with osteoporosis medications publication-title: Calcif Tissue Int doi: 10.1007/s00223-009-9329-4 – volume: 19 start-page: 1233 year: 2010 end-page: 1240 ident: CR24 article-title: Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.2048 – volume: 361 start-page: 756 year: 2009 end-page: 765 ident: CR20 article-title: Denosumab for prevention of fractures in postmenopausal women with osteoporosis publication-title: N Engl J Med doi: 10.1056/NEJMoa0809493 – volume: 23 start-page: 1569 year: 2008 ident: 1780_CR27 publication-title: J Bone Miner Res doi: 10.1359/jbmr.080510 – volume: 20 start-page: 23 year: 2009 ident: 1780_CR28 publication-title: Osteoporos Int doi: 10.1007/s00198-008-0644-9 – volume: 354 start-page: 821 year: 2006 ident: 1780_CR17 publication-title: N Engl J Med doi: 10.1056/NEJMoa044459 – volume: 43 start-page: 1203 year: 2005 ident: 1780_CR8 publication-title: Med Care doi: 10.1097/01.mlr.0000185733.30697.f6 – volume: 22 start-page: 1832 year: 2007 ident: 1780_CR18 publication-title: J Bone Miner Res doi: 10.1359/jbmr.070809 – volume: 19 start-page: 1233 year: 2010 ident: 1780_CR24 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.2048 – volume: 5 start-page: 618 year: 2005 ident: 1780_CR15 publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2005.06.005 – volume: 82 start-page: 1493 year: 2007 ident: 1780_CR2 publication-title: Mayo Clin Proc doi: 10.4065/82.12.1493 – volume: 86 start-page: 202 year: 2010 ident: 1780_CR4 publication-title: Calcif Tissue Int doi: 10.1007/s00223-009-9329-4 – volume: 5 start-page: 389 year: 2000 ident: 1780_CR9 publication-title: Psychol Health Med doi: 10.1080/713690213 – volume: 20 start-page: 1291 year: 2004 ident: 1780_CR25 publication-title: Curr Med Res Opin doi: 10.1185/030079904125004475 – volume: 90 start-page: 217 year: 2006 ident: 1780_CR13 publication-title: J Affect Disord doi: 10.1016/j.jad.2005.08.018 – volume: 24 start-page: 153 year: 2009 ident: 1780_CR19 publication-title: J Bone Miner Res doi: 10.1359/jbmr.0809010 – volume: 15 start-page: 728 year: 2009 ident: 1780_CR7 publication-title: J Manag Care Pharm doi: 10.18553/jmcp.2009.15.9.728 – volume: 361 start-page: 756 year: 2009 ident: 1780_CR20 publication-title: N Engl J Med doi: 10.1056/NEJMoa0809493 – volume: 38 start-page: S2 year: 2006 ident: 1780_CR14 publication-title: Bone doi: 10.1016/j.bone.2006.01.150 – volume: 21 start-page: 837 year: 2010 ident: 1780_CR11 publication-title: Osteoporos Int doi: 10.1007/s00198-009-1023-x – volume: 23 start-page: S210 year: 2008 ident: 1780_CR23 publication-title: J Bone Miner Res – volume: 81 start-page: 1013 year: 2006 ident: 1780_CR3 publication-title: Mayo Clin Proc doi: 10.4065/81.8.1013 – volume: 21 start-page: 1943 year: 2010 ident: 1780_CR1 publication-title: Osteoporos Int doi: 10.1007/s00198-009-1134-4 – volume: 14 start-page: 1 year: 1999 ident: 1780_CR22 publication-title: Psychol Health doi: 10.1080/08870449908407311 – volume: 22 start-page: 967 year: 2011 ident: 1780_CR29 publication-title: Osteoporos Int doi: 10.1007/s00198-010-1424-x – volume: 296 start-page: 2927 year: 2006 ident: 1780_CR26 publication-title: JAMA doi: 10.1001/jama.296.24.2927 – volume: 19 start-page: 1059 year: 2004 ident: 1780_CR16 publication-title: J Bone Miner Res doi: 10.1359/JBMR.040305 – volume: 17 start-page: 205 year: 2006 ident: 1780_CR12 publication-title: Ann Oncol doi: 10.1093/annonc/mdj044 – volume: 15 start-page: 1003 year: 2004 ident: 1780_CR5 publication-title: Osteoporos Int doi: 10.1007/s00198-004-1652-z – volume: 38 start-page: 922 year: 2006 ident: 1780_CR6 publication-title: Bone doi: 10.1016/j.bone.2005.10.022 – volume: 15 start-page: 38 year: 2004 ident: 1780_CR10 publication-title: Int J STD AIDS doi: 10.1258/095646204322637245 – ident: 1780_CR21 doi: 10.1007/s00198-010-1378-z
SSID	ssj0007997
Score	2.5021722
Snippet	Summary The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and... The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	317
SubjectTerms	Administration, Oral Aged Alendronate - administration & dosage Alendronate - adverse effects Alendronate - therapeutic use Alendronic acid Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bisphosphonates Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Bone mineral density Clinical trials Comparative studies Cross-Over Studies Denosumab Drug Administration Schedule Drug therapy Endocrinology Female Humans Injections, Subcutaneous Medication Adherence Medicine Medicine & Public Health Middle Aged Original Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology Patient Preference Post-menopause RANK Ligand - antagonists & inhibitors Rheumatology Tablets Treatment Outcome Womens health
SummonAdditionalLinks	– databaseName: SpringerLink Contemporary dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQixAX3pSlBc2BA49aihMnTnpbUSouVCstoL1Fju1oV9omVbPhwO_pD-1MHqZLoRKcPY4mzjjzjWf8DWNv4kAWQquSp1FiucSggmeRLbjSpsCxVCnTN5tQp6fpYpHNhnvczVjtPqYkuz-1v-xGaIQKrwQXKg04hjy7MZHNUIg-_-5_vyrrOqpgpK54JsViTGX-6RHbzugGwrxZKPlbtrRzQicP_0v9R-zBgDlh2hvJY3bHVU_YvS9DVv0pu6QmvWvAwLtdbxqoS0BUCMfT2RzeHhOZeHumC5jaZX81EGa-NwnMr12OeAcdV-0RaAglR_PeLA8BXaGtz1Y_nT2EbhGoZBSM734IdBAM6KWIOKFC4AurCs7rhorfMZ5vG1SsY4l4xr6dfPr68TMfujdwEwfBhutSOumMNaHTInY6S6PA4tcJbRZoITQ6QqtKlwaxMWhICFOMdogeTJTFuhBl9JztVHXlXjBIIpeIJC5LUZYyFkUayUSYQjlXWGuEnrBg_Iy5GajNqcPGOvekzN3q57j6Oa1-LibsvZ9y3vN63Ca8P9pGPmzxJs8EQS8pwwkDP4p7kxIuunJ1iyIhsQshQr5NJEmJLyiZsL3e1rw66EuI3REnqy0r9ALEDL49Uq2WHUN4RDyQAvX-MNriL73_-pYv_0l6n91H7Bj2p1EHbGdz0bpX7K75gWZ38brbklfP1TR8 priority: 102 providerName: Springer Nature
Title	Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
URI	https://link.springer.com/article/10.1007/s00198-011-1780-1 https://www.ncbi.nlm.nih.gov/pubmed/21927922 https://www.proquest.com/docview/913175442 https://www.proquest.com/docview/920228932 https://www.proquest.com/docview/926882376 https://pubmed.ncbi.nlm.nih.gov/PMC3249211
Volume	23
WOSCitedRecordID	wos000298645700030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1433-2965 dateEnd: 20161231 omitProxy: false ssIdentifier: ssj0007997 issn: 0937-941X databaseCode: 7X7 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1433-2965 dateEnd: 20241214 omitProxy: false ssIdentifier: ssj0007997 issn: 0937-941X databaseCode: 7RV dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1433-2965 dateEnd: 20161231 omitProxy: false ssIdentifier: ssj0007997 issn: 0937-941X databaseCode: BENPR dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1433-2965 dateEnd: 20161231 omitProxy: false ssIdentifier: ssj0007997 issn: 0937-941X databaseCode: 8C1 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Journals customDbUrl: eissn: 1433-2965 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007997 issn: 0937-941X databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZgFyEuyxvKQjUHDjzW2jgvJ1xQ2Ye4UFUtrHqLHNtRK3WT7rbhwO_hhzLjpIGyohcukSI7ih1_zszY4-9j7HXkhblQsuBJEBseYlDB08DkXCqdY1kipW7EJuRwmEyn6ajNzVm1aZWbf6L7UZtK0xr5cSrI0oWh_3F5xUk0ijZXWwWN22yfVLMJ5nLaxVueTJ22CsbskqehmG42NT3HISrobBnlc8nE42LbLN3wNW-mTP61b-rM0fn9_-zIA3bQ-qEwaIDzkN2y5SN290u70_6Y_STh3gVgMF4v1iuoCkBPEU4Howm8OSWC8fpS5TAws-a4IIw6vRKY_HFg4i04_toPoMAPOb57PTsCNI-mupz_sOYI3OegNFLQnSIi0OIwoOUiMoUSnWGYl7CsVpQQjzF-vcKGOeaIJ-zb-dnXk8-8VXTgOvK8NVdFaEOrjfatEpFVaRJ4BsfJN6mnhFBoHI0sbOJFWiO40HXRyqJHoYM0Urkogqdsr6xK-5xBHNhYxFFRiKIII5EnQRgLnUtrc2O0UD3mbQY00y3dOaluLLKOqNlhIEMMZISBTPTYu-6RZcP1savy4WZ4s3bar7JubHsMulKcr7QJo0pb1VjFJ8Yh9Jp3VYkT4hCKe-xZg7quOWhfiPERH5ZbeOwqEFv4dkk5nznW8IC4IQW2-_0Gub_b_c9evtjZy0N2D_1Hv1mResn21te1fcXu6O8Is-s-TsbxRd9NSXdN8JqciD7b_3Q2HI3xbjy5-AVjU0Pa
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMAL90sZl_MAEpdZ2IkTJ0gIVSvTpm1VpQ2pb8GxHbVSl5SmBcHv4ZX_yHHSZJSJvu2BZ9uR7Xw-59g-_j5CngdMpFzJjEZ-aKjATQWNfZNSqXSKZZGUuhabkP1-NBzGgw3yq3kL49IqG5tYGWpTaHdG_jbmztMJ4X2YfqFONMpdrjYKGjUqDuz3b7hjK9_v9_D3vvC83Y8nO3t0KSpAdcDYnKpMWGG10Z5VPLAqjnxmmIw9EzPFuUL7bGRmIxZojeND76mVRaem_ThQKc98_O4lcln4nu8WUbRzllEi40rLhaHHp7Hgw-YSlVWcpdy9ZXP5YzJilK-6wXOx7fkUzb_uaSv3t3vzP5u4W-TGMs6Gbr0wbpMNm98hV4-WmQR3yU8nTDyBmS0Xk3kJRQYYCUOvOziGlz1HoL44VSl0zah-DgmDVo8Fjv94EPIKKn7ed6DAExTHOh9tA7p_U5yOf1izDdX0uzRZ0K3iI7jDb0DP7Mgicgz2YZzDtChdwn8xVYsSO1YxY9wjny5kju6TzbzI7UMCoW9DHgZZxrNMBDyNfBFynUprU2M0Vx3CGgAleknn7lRFJklLRF1hLkHMJQ5zCe-Q122Tac1lsq7yVgOnZGnWyqTFUodAW4r2yF0yqdwWC6ziOUYl3BWsqxJGjiMp7JAHNcrb7qD_dIyW2Fiu4L-t4NjQV0vy8ahiRfcd9yXHfr9pVspZv_85ykdrR_mMXNs7OTpMDvf7B1vkOsbKXn369phszmcL-4Rc0V8RcrOnlSEA8vmiF9BvF86d4Q
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLZGhyZeuF_KuJwHkLjMmp2bEySECl3FNKgqNqS-Bcd21EpdUpoWBL-HP8G_4zg3KBN92wPPdiI7-c7NPuc7hDzymZdwKVIauoGmHgYVNHJ1QoVUCY6FQqiq2YQYDsPxOBptkZ9NLYxNq2x0Yqmoda7sGfl-xK2l8zxnP62zIkb9wav5Z2obSNmL1qabRoWQI_PtK0ZvxcvDPv7qx44zODh585bWDQao8hlbUpl6xjNKK8dI7hsZhS7TTESOjpjkXKKu1iI1IfOVwr2iJVXSoIFTbuTLhKcuvvcC2RYuxjwdsv36YDj60JoBEZWdXRjafxp5fNxcqbKSwZTbyjabTSZCRvm6UTzj6Z5N2Pzr1rY0hoMr__FnvEou1x449CqRuUa2THad7LyvcwxukB-2ZfEMFqZYzZYF5Cmgjwz93ugYnvQttfrqVCbQ05OqUBJGbacWOP6jVOQplMy9L0CC41Hc63KyB-gY6Px0-t3oPSh_hU2gBdX2ggR7LA5osy2NRIZhAEwzmOeFLQXI53JV4MJKzoyb5OO5fKNbpJPlmblDIHBNwAM_TXmaej5PQtcLuEqEMYnWissuYQ2YYlUTvdt-I7O4pagu8Rcj_mKLv5h3ybP2kXnFcrJp8m4DrbhWeEXc4qpLoB1FTWWvn2Rm8hVOcSzXEsYLm6YEoWVPCrrkdoX4djloWS3XJT4s1mShnWB50tdHsumk5Et3LSsmx3U_b6Tm97r_ucu7G3f5kOyg3MTvDodHu-QSOtFOdSx3j3SWi5W5Ty6qL4i4xYNaKwD5dN4S9Av8Qag_
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Final+results+of+the+DAPS+%28Denosumab+Adherence+Preference+Satisfaction%29+study%3A+a+24-month%2C+randomized%2C+crossover+comparison+with+alendronate+in+postmenopausal+women&rft.jtitle=Osteoporosis+international&rft.au=Freemantle%2C+N&rft.au=Satram-hoang%2C+S&rft.au=Tang%2C+E-t&rft.au=Kaur%2C+P&rft.date=2012-01-01&rft.pub=Springer+Nature+B.V&rft.issn=0937-941X&rft.eissn=1433-2965&rft.volume=23&rft.issue=1&rft.spage=317&rft_id=info:doi/10.1007%2Fs00198-011-1780-1&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=2550843201
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0937-941X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0937-941X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0937-941X&client=summon